MHS
VTGN icon

M Holdings Securities’s VistaGen Therapeutics VTGN Stock Holding History

M Holdings Securities’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$205K Buy
2,167
+34
+2% +$2.52K 0.02% 227
2021
Q1 		$136K Buy
+2,133
New +$142K 0.01% 480

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

M Holdings Securities's VTGN Position: Q2 2021 in Review

M Holdings Securities increased its VistaGen Therapeutics (VTGN) stake by 1.6% in Q2 2021, buying an estimated $2.52K and bringing the position to 2,167 shares worth $205K. The position accounts for 0.02% of the portfolio, ranked #227.

M Holdings Securities first reported a position in VTGN in Q1 2021 and has held it in 2 quarters since. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

  • M Holdings Securities held 2,167 shares of VistaGen Therapeutics worth $205K as of Q2 2021.
  • M Holdings Securities bought 34 VistaGen Therapeutics shares in Q2 2021, an estimated $2.52K.
  • VistaGen Therapeutics made up 0.02% of M Holdings Securities's portfolio in Q2 2021, its #227 holding.
  • M Holdings Securities first reported a position in VistaGen Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on M Holdings Securities's 13F filing for Q2 2021, filed 19 Aug 2021.